Drug Trial Radar · NCT04600167
Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Mar 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,000
Planned (sponsor's estimate)
Start
Jun 17, 2022
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Dr. Nyanda Elias NtinginyaGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Stichting Katholieke Universiteit- Radboudumc (RUMC), Netherlands; Otago University, New Zealand; Makerere University; St George's, University of London; Kilimanjaro Christian Medical University College (KCMUCo), Tanzania; Uganda Martyrs Hospital Lubaga, Uganda; King's College London
- First posted
- Oct 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Diabetes mellitus (DM) increases susceptibility to Tuberculosis (TB) and worsens TB patient outcomes. The number of patients with combined TB and DM now outnumbers that of combined TB and HIV and it has been estimated that 15-30% of TB disease may be attributable to diabetes globally. This may be expected to rise substantially as DM prevalence increases. Treatment of Latent TB Infection (LTBI) in this population will likely have a significant clinical benefit. Similar to HIV-infected individuals, those with DM might benefit from therapy to prevent the development of TB disease. Current international guidelines do not recommend LTBI management in people with DM, but this is because no studies have examined the risk-benefit ratio of such an intervention. To date, no RCTs have been conducted to investigate the efficacy and safety of preventive treatment of LTBI in DM patients. Based on evidence on effectiveness, safety, and treatment completion rates, 3HP has been selected as the regimen of choice for this study of African people living with DM. People living with DM will be randomized to 3HP or placebo to determine the efficacy of 3HP in the prevention of TB disease in this population. PROTID's preventive treatment of LTBI among people with DM will generate the first solid evidence to support or refute the use of preventive treatment against TB in people with DM.
Conditions
- Diabetes Mellitus
- Tuberculosis
Interventions
Isoniazid and Rifapentine (INH-RPT)Drug
Oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.
PlaceboDrug
Participants in the control group will receive placebo once weekly for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- First diagnosis of TBTime frame: Through study completion, median of 33 months follow-up
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Mbeya zonal referral hospital
Mbeya, Tanzania · Recruiting
Kilimanjaro Christian Medical Center
Moshi, Tanzania · Recruiting
Makerere University
Kampala, Uganda · Recruiting
Martyrs Hospital Lubaga
Kampala, Uganda · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.